Etiology, extended-spectrum β-lactamase rates and antimicrobial susceptibility of gram-negative bacilli causing intra-abdominal infections in patients in general pediatric and pediatric intensive care units - Global data from the study for monitoring antimicrobial resistance trends 2008 to 2010

Pediatric Infectious Disease Journal

Volumn 32, Issue 6, 2013, Pages 636-640

  Badal, Robert E ^a   Bouchillon, Samuel K ^a   Lob, Sibylle H ^a   Hackel, Meredith A ^a   Hawser, Stephen P ^b   Hoban, Daryl J ^a  

^a International Health Management Associates   (United States)

^b International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

Extended spectrum lactamase; Intensive care unit; Resistance; Surveillance

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFEPIME; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; QUINOLONE DERIVATIVE;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CITROBACTER FREUNDII; CONCENTRATION RESPONSE; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; GRAM NEGATIVE INFECTION; IN VITRO STUDY; INTENSIVE CARE UNIT; KLEBSIELLA OXYTOCA; NONHUMAN; PEDIATRIC WARD; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; SERRATIA MARCESCENS; SPECIES DISTRIBUTION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, PEDIATRIC; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS, PEDIATRIC; INTRAABDOMINAL INFECTIONS; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 84879229868     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182886377     Document Type: Article

References (19)

1. Giske CG, Monnet DL, Cars O, et al.; ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008;52:813-821.
2. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med. 2009;37: 1463-1469.
3. Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23:320-326.
4. Hoban DJ, Bouchillon SK, Hawser S P, et al. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diag Microbiol Infect Dis. 2010;66:78-86.
5. Hawser S P, Bouchillon SK, Hoban DJ, et al. Epidemiologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002-2007 from the SMART study. Surg Infect (Larchmt). 2010;11:371-378.
6. Cantón R, Novais A, Valverde A, et al. Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect. 2008;14(suppl 1):144-153.
7. Pitout JDD, Nordmann P, Laupland KB, et al. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56:52-59.
8. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008;13:19044.
9. Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007;59:165-174.
10. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39:2206-2212.
11. Rodríguez-Baño J, Picón E, Gijón P, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol. 2010;48:1726-1731.
12. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta- lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51: 1987-1994.
13. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standards. 8th ed. Wayne, PA: CLSI document M07-A8; 2009.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. Wayne, PA: CLSI Document M100-S21; 2011.
15. Hoban DJ, Lascols C, Nicolle LE, et al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. Diagn Microbiol Infect Dis. 2012;74:62-67.
16. Souli M, Kontopidou F V, Koratzanis E, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother. 2006;50:3166-3169.
17. Jamal WY, Al Hashem G, Khodakhast F, et al. Comparative in vitro activity of tigecycline and nine other antibiotics against gram-negative bacterial isolates, including ESBL-producing strains. J Chemother. 2009;21:261-266.
18. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta- lactamaseproducing organisms. J Hosp Infect. 2009;73:345-354.
19. Badal R, Bouchillon S, Hoban D, et al. Global trends in frequency and susceptibility of extended-spectrum beta-lactamase-positive E. coli, K. pneumoniae, and K. oxytoca isolated from intra-abdominal infections from 2003-2007 - The SMART Study [Abstract C1-131]. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the 46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008. Washington, DC: American Society for Microbiology; 2008.